Regeneron Pharmaceuticals and partner Sanofi are cutting the list price of their heart drug alirocumab (Praluent) by 60 percent, the latest acknowledgement that the treatment—which has shown a striking ability to lower cholesterol, but has struggled to sell because of its high price tag—isn’t getting to the patients who need it.
Starting in early March, Regeneron (NASDAQ: REGN) and Sanofi (NYSE: SNY) will slash alirocumab’s per year list price from roughly $14,000 to $5,850. The move mirrors an October announcement from Amgen (NASDAQ: AMGN), which also cut the list price of its similar, rival drug evolocumab (Repatha) to… Read more »
UNDERWRITERS AND PARTNERS
Categories: Biotech, Boston blog main, Boston top stories, clinical trials, Drugs, Express Scripts, FDA, Industry, Life Sciences, National blog main, National top stories, new york, New York blog main, New York top stories, Regeneron Pharmaceuticals, San Francisco blog main, San Francisco top stories, Sanofi